Possible Mechanism and Pharmacological Activities of a Flavolignan
Silibinin

Hemlata      Bhardwaj; Neeru      Vasudeva; Sunil      Sharma
Abstract

Silymarin, a flavonolignan derived from the seeds extract of Silybum marianum (milk thistle), has been frequently used since ancient times. It is made up of flavonolignans such as silychristin, isosilybin A and B, dehydrosilybin, and silybin as well as flavonoids like taxifolin, with silibinin being the most active. Silibinin is a diastereoisomeric combination of two flavonolignans, silybin A and silybin B, with a diastereoisomeric structure. It is found in a variety of phytopreparations that are used to prevent and treat liver disorders. It is considered an important component in a huge range of cosmetic, pharmacological, and medical formulations. Several investigations have revealed that silibinin has anticancer and chemopreventive properties, as well as hypocholesterolaemic, antimicrobial, antidiabetic, anticancer, antihypertension, antiparkinson, antiinflammatory, antioxidant, cardioprotective, and neuroprotective benefits by the help of different mechanisms such as inducing apoptosis, decreasing cell proliferation, inhibiting angiogenesis and viral transition and its entry, and also regulating insulin secretion by decreasing or increasing the expression of sterol regulatory element binding protein-1c (SREBP-1C) and insig-1 transcription factor, etc. Silibinin data is gathered from many public databanks in order to emphasize its important role in the treatment or prevention of various diseases.
Graphical Abstract

[1]
Dai, J.P.; Wu, L.Q.; Li, R.; Zhao, X.F.; Wan, Q.Y.; Chen, X.X.; Li, W.Z.; Wang, G.F.; Li, K.S. Identification of 23-(s)-2-amino-3-phenylpropanoyl-silybin as an antiviral agent for influenza A virus infection in vitro and in vivo. Antimicrob. Agents Chemother.,  2013, 57(9), 4433-4443.
 [http://dx.doi.org/10.1128/AAC.00759-13] [PMID: 23836164]

[2]
Sharma, G.; Singh, R.P.; Chan, D.C.; Agarwal, R. Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res.,  2003, 23(3B), 2649-2655.
 [PMID: 12894553]

[3]
Muchiri, R.N.; van Breemen, R.B. Single laboratory validation of UHPLC-MS/MS assays for six milk thistle flavonolignans in human serum. J. AOAC Int.,  2021, 104(1), 232-238.
 [http://dx.doi.org/10.1093/jaoacint/qsaa033] [PMID: 33251548]

[4]
Vogel, G.; Trost, T.; Braat, R. Studies on the pharmacodynamics. Including site and mode of action, of silymarin: the antihepatotoxic principle from Silybum mar. (L). Gaertn. Arzneim. Forsch,  1975, 25, 82-89.

[5]
Otkur, W.; Liu, W.; Wang, J.; Jia, X.; Huang, D.; Wang, F.; Hayashi, T.; Tashiro, S.; Onodera, S.; Ikejima, T. Sub-lethal ultraviolet B irradiation and Poly I:C treatment synergistically induced apoptosis of HaCaT cells through NF-κB pathway. Mol. Immunol.,  2018, 99, 19-29.
 [http://dx.doi.org/10.1016/j.molimm.2018.04.001] [PMID: 29674236]

[6]
Hahn, V.G.; Lehmann, H.D.; Kurten, M.; Uebcl, H.; Vogel, G. Pharmacology and toxicology of silymarin. The anti-hepatotoxic agent of Silvlutm imirinmtm (L.) Gaertn. Arzneimittelforschung,  1968, 18(6), 698-704.

[7]
Ghosh, A.; Ghosh, T.; Jain, S. Silymarin- a review on the pharmacodynamics and bioavailability enhancement approaches. J. Pharm. Sci. Technol.,  2010, 2, 348-355.

[8]
Dixit, N.; Baboota, S.; Kohli, K.; Ahmad, S.; Ali, J. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J. Pharmacol.,  2007, 39(4), 172.
 [http://dx.doi.org/10.4103/0253-7613.36534]

[9]
Mallikarjuna, G.; Dhanalakshmi, S.; Singh, R.P.; Agarwal, C.; Agarwal, R. Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res.,  2004, 64(17), 6349-6356.
 [http://dx.doi.org/10.1158/0008-5472.CAN-04-1632] [PMID: 15342425]

[10]
Agarwal, R.; Katiyar, S.K.; Lundgren, D.W. Mukhtar, Inhibitory effect of silymarin. An anti-hepatotoxic flavonoid, on β-O-tetradecanoylphorbol-B-acetate induced epidermal omithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis,  1994, 5, 1099-1103.

[11]
Wen, Z.; Dumas, T.E.; Schrieber, S.J.; Hawke, R.L.; Fried, M.W.; Smith, P.C. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab. Dispos.,  2008, 36(1), 65-72.
 [http://dx.doi.org/10.1124/dmd.107.017566] [PMID: 17913795]

[12]
Hlangothia, D.; Abdel Rahman, F.; Nguyen, T. Distribution of silymarin in the fruit of Silybum marianum L. Pharm. Anal. Acta,  2016, 7(11)1000511
 [http://dx.doi.org/10.4172/2153-2435.1000511]

[13]
Kaur, A.K.; Wahi, A.; Brijesh, K.; Bhandari, A.; Prasad, N. Milk thistle (Silybum marianum): a review. IJPRD,  2011, 3, 1-10.

[14]
Wu, J.W.; Lin, L.C.; Tsai, T.H. Drug–drug interactions of silymarin on the perspective of pharmacokinetics. J. Ethnopharmacol.,  2009, 121(2), 185-193.
 [http://dx.doi.org/10.1016/j.jep.2008.10.036] [PMID: 19041708]

[15]
Milić, N.; Milošević, N.; Suvajdžić, L.; Žarkov, M.; Abenavoli, L. New therapeutic potentials of milk thistle (Silybum marianum). Nat. Prod. Commun.,  2013, 8(12), 1934578X1300801.
 [http://dx.doi.org/10.1177/1934578X1300801236] [PMID: 24555302]

[16]
Federico, A.; Dallio, M.; Loguercio, C.; Tsai, T-H.; Jeon, Y. Silymarin/silybin and chronic liver disease: A marriage of many years. Molecules,  2017, 22(2), 191.
 [http://dx.doi.org/10.3390/molecules22020191] [PMID: 28125040]

[17]
Xu, F.; Yang, J.; Negishi, H.; Sun, Y.; Li, D.; Zhang, X.; Hayashi, T.; Gao, M.; Ikeda, K.; Ikejima, T. Silibinin decreases hepatic glucose production through the activation of gut–brain–liver axis in diabetic rats. Food Funct.,  2018, 9(9), 4926-4935.
 [http://dx.doi.org/10.1039/C8FO00565F] [PMID: 30178798]

[18]
Liu, B.; Liu, W.; Liu, P.; Liu, X.; Song, X.; Hayashi, T.; Onodera, S.; Ikejima, T. Silibinin alleviates the learning and memory defects in over trained rats accompanying reduced neuronal apoptosis and senescence. Neurochem. Res.,  2019, 44(8), 1818-1829.
 [http://dx.doi.org/10.1007/s11064-019-02816-2] [PMID: 31102026]

[19]
Raina, K.; Agarwal, R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacol. Sin.,  2007, 28(9), 1466-1475.
 [http://dx.doi.org/10.1111/j.1745-7254.2007.00691.x] [PMID: 17723180]

[20]
Wu, K.; Zeng, J.; Zhu, G.; Zhang, L.; Zhang, D.; Li, L.; Fan, J.; Wang, X.; He, D. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol. Sin.,  2009, 30(8), 1162-1168.
 [http://dx.doi.org/10.1038/aps.2009.94] [PMID: 19578386]

[21]
Zi, X.; Grasso, A.W.; Kung, H-J.; Agarwal, R. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res.,  1998, 58(9), 1920-1929.
 [PMID: 9581834]

[22]
Arthur, C.R.; Morton, S.L.; Dunham, L.D.; Keeney, P.M.; Bennett, J.P., Jr Parkinson’s disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance. Mol. Neurodegener.,  2009, 4(1), 37.
 [http://dx.doi.org/10.1186/1750-1326-4-37] [PMID: 19775436]

[23]
Mourclle, M.; Muriel, P.; Favari, L.; Franco, T. Prevention of CCI4-induced liver cirrhosis by silymarin. Fundam. Clin. Pharmacol.,  1989, 3, 183-191.
 [http://dx.doi.org/10.1111/j.1472-8206.1989.tb00449.x]

[24]
Radjabian, T.; Fallah Huseini, H. Anti-hyperlipidemic and anti-atherosclerotic activities of silymarins from cultivated and wild plants of Silybum marianum L. with different content of flavonolignans. Iran J pharmacol. Ther,  2010, 9, 63-67.

[25]
Yan, W.J.; Tan, Y.C.; Xu, J.C.; Tang, X.P.; Zhang, C.; Zhang, P.B.; Ren, Z.Q. Protective effects of silibinin and its possible mechanism of action in mice exposed to chronic unpredictable mild stress. Biomol. Ther. (Seoul),  2015, 23(3), 245-250.
 [http://dx.doi.org/10.4062/biomolther.2014.138] [PMID: 25995823]

[26]
Bosisio, E.; Benelli, C.; Pirola, O. Effect of the flavanolignans of Silybum marianum L. On lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol. Res.,  1992, 25(2), 147-165.
 [http://dx.doi.org/10.1016/1043-6618(92)91383-R] [PMID: 1635893]

[27]
Mashhadi Akbar Boojar, M.; Mashhadi Akbar Boojar, M.; Golmohammad, S. Overview of Silibinin anti-tumor effects. J. Herb. Med.,  2020, 23100375
 [http://dx.doi.org/10.1016/j.hermed.2020.100375]

[28]
Althagafy, H.S.; Meza-Aviña, M.E.; Oberlies, N.H.; Croatt, M.P. Mechanistic study of the biomimetic synthesis of flavonolignan diastereoisomers in milk thistle. J. Org. Chem.,  2013, 78(15), 7594-7600.
 [http://dx.doi.org/10.1021/jo4011377] [PMID: 23876147]

[29]
Lani, R.; Hassandarvish, P.; Chiam, C.W.; Moghaddam, E.; Chu, J.J.H.; Rausalu, K.; Merits, A.; Higgs, S.; Vanlandingham, D.; Abu Bakar, S.; Zandi, K. Antiviral activity of silymarin against chikungunya virus. Sci. Rep.,  2015, 5(1), 11421.
 [http://dx.doi.org/10.1038/srep11421] [PMID: 26078201]

[30]
Hansel, R.; Rimpler, H. Structure of silybin: Synthetic studies. Dtsch. Apoth. Ztg.,  1968, 108, 1985.

[31]
Bai, D.; Jin, G.; Yin, S.; Zou, D.; Zhu, Q.; Yang, Z.; Liu, X.; Ren, L.; Sun, Y.; Gan, S. Antioxidative and anti-apoptotic roles of silibinin in reversing learning and memory deficits in APP/PS1 mice. Neurochem. Res.,  2017, 42(12), 3439-3445.
 [http://dx.doi.org/10.1007/s11064-017-2389-3] [PMID: 28852940]

[32]
Biedermann, D. Vavříková, E.; Cvak, L.; Křen, V. Chemistry of silybin. Nat. Prod. Rep.,  2014, 31(9), 1138-1157.
 [http://dx.doi.org/10.1039/C3NP70122K] [PMID: 24977260]

[33]
Bijak, M. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.) - Chemistry, bioavailability, and metabolism. Molecules,  2017, 22(11), 1942.
 [http://dx.doi.org/10.3390/molecules22111942] [PMID: 29125572]

[34]
Kim, Y.C.; Kim, E.J.; Lee, E.D.; Kim, J.H.; Jang, S.W.; Kim, Y.G.; Kwon, J.W.; Kim, W.B.; Lee, M.G. Comparative bioavailability of silibinin in healthy male volunteers. Int. J. Clin. Pharmacol. Ther.,  2003, 41(12), 593-596.
 [http://dx.doi.org/10.5414/CPP41593] [PMID: 14692709]

[35]
Hänsel, R.; Schulz, J.; Pelter, A. Structure of silybin: synthetic studies. J. Chem. Soc. Chem. Commun.,  1972, 1(3), 195-196.
 [http://dx.doi.org/10.1039/C39720000195]

[36]
Ambani, L.M.; Van Woert, M.H.; Murphy, S. Brain peroxidase and catalase in Parkinson disease. Arch. Neurol.,  1975, 32(2), 114-118.
 [http://dx.doi.org/10.1001/archneur.1975.00490440064010] [PMID: 1122174]

[37]
Wianowska, D. Wi niewski, M. Simplified procedure of silymarin extraction from Silybum marianum L. Gaertner. J. Chromatogr. Sci.,  2015, 53(2), 366-372.
 [http://dx.doi.org/10.1093/chromsci/bmu049] [PMID: 24895445]

[38]
Gažák, R.; Purchartová, K.; Marhol, P.; Živná, L.; Sedmera, P.; Valentová, K.; Kato, N.; Matsumura, H.; Kaihatsu, K. Křen, V. Antioxidant and antiviral activities of silybin fatty acid conjugates. Eur. J. Med. Chem.,  2010, 45(3), 1059-1067.
 [http://dx.doi.org/10.1016/j.ejmech.2009.11.056] [PMID: 20036447]

[39]
Hogan, F.S.; Krishnegowda, N.K.; Mikhailova, M.; Kahlenberg, M.S. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J. Surg. Res.,  2007, 143(1), 58-65.
 [http://dx.doi.org/10.1016/j.jss.2007.03.080] [PMID: 17950073]

[40]
Hussain, S.A.; Jassim, N.A.; Numan, I.T.; Al-Khalifa, I.I.; Abdullah, T.A. Anti-inflammatory activity of silymarin in patients with knee osteoarthritis. A comparative study with piroxicam and meloxicam. Saudi Med. J.,  2009, 30(1), 98-103.
 [PMID: 19139781]

[41]
Prasad, R.R.; Paudel, S.; Raina, K.; Agarwal, R. Silibinin and non-melanoma skin cancers. J. Tradit. Complement. Med.,  2020, 10(3), 236-244.
 [http://dx.doi.org/10.1016/j.jtcme.2020.02.003] [PMID: 32670818]

[42]
AbouZid, S. Silymarin, Natural Flavonolignans from Milk Thistle. In Phytochemicals-a Global Perspective of Their Role in Nutrition and Health; InTech: London, UK, 2012, pp. 255-272.

[43]
Kurkin, V.A. Phenylpropanoids from medicinal plants: Distribution, classification, structural analysis, and biological activity. Chem. Nat. Compd.,  2003, 39(2), 123-153.
 [http://dx.doi.org/10.1023/A:1024876810579]

[44]
Giorgi, V.S.I.; Peracoli, M.T.S.; Peracoli, J.C.; Witkin, S.S.; Bannwart-Castro, C.F. Silibinin modulates the NF-κb pathway and pro-inflammatory cytokine production by mononuclear cells from preeclamptic women. J. Reprod. Immunol.,  2012, 95(1-2), 67-72.
 [http://dx.doi.org/10.1016/j.jri.2012.06.004] [PMID: 22871551]

[45]
Wang, X.; Michaelis, E.K. Selective neuronal vulnerability to oxidative stress in the brain. Front. Aging Neurosci.,  2010, 2, 12.
 [http://dx.doi.org/10.3389/fnagi.2010.00012] [PMID: 20552050]

[46]
Calani, L.; Brighenti, F.; Bruni, R.; Del Rio, D. Absorption and metabolism of milk thistle flavanolignans in humans. Phytomedicine,  2012, 20(1), 40-46.
 [http://dx.doi.org/10.1016/j.phymed.2012.09.004] [PMID: 23072776]

[47]
Nyiredy, S.; Samu, Z.; Szücs, Z.; Gulácsi, K.; Kurtán, T.; Antus, S. New insight into the biosynthesis of flavanolignans in the white-flowered variant of Silybum marianum. J. Chromatogr. Sci.,  2008, 46(2), 93-96.
 [http://dx.doi.org/10.1093/chromsci/46.2.93] [PMID: 18366865]

[48]
Zi, X.; Feyes, D.K.; Agarwal, R. Anti-carcinogenic effect of a flavonoid antioxidant silymarin in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of CDKs and associated cyclins. Clin. Cancer Res.,  1998, 4, 1055-1064.
 [PMID: 9563902]

[49]
Joshi, R.; Garabadu, D.; Teja, G.R.; Krishnamurthy, S. Silibinin ameliorates LPS-induced memory deficits in experimental animals. Neurobiol. Learn. Mem.,  2014, 116, 117-131.
 [http://dx.doi.org/10.1016/j.nlm.2014.09.006] [PMID: 25444719]

[50]
Vargas-Mendoza, N.; Madrigal-Santillán, E.; Morales-González, A.; Esquivel-Soto, J.; Esquivel-Chirino, C.; García-Luna, Y. González-Rubio, M.; Gayosso-de-Lucio, J.A.; Morales-González, J.A. Hepatoprotective effect of silymarin. World J. Hepatol.,  2014, 6(3), 144-149.
 [http://dx.doi.org/10.4254/wjh.v6.i3.144] [PMID: 24672644]

[51]
Cheng, B.; Gong, H.; Li, X.; Sun, Y.; Zhang, X.; Chen, H.; Liu, X.; Zheng, L.; Huang, K. Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide. Biochem. Biophys. Res. Commun.,  2012, 419(3), 495-499.
 [http://dx.doi.org/10.1016/j.bbrc.2012.02.042] [PMID: 22366091]

[52]
Agarwal, C.; Singh, R.P.; Dhanalakshmi, S.; Tyagi, A.K.; Tecklenburg, M.; Sclafani, R.A.; Agarwal, R. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene,  2003, 22(51), 8271-8282.
 [http://dx.doi.org/10.1038/sj.onc.1207158] [PMID: 14614451]

[53]
Singh, R.P.; Sharma, G.; Dhanalakshmi, S.; Agarwal, C.; Agarwal, R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol. Biomarkers Prev.,  2003, 12(9), 933-939.
 [PMID: 14504208]

[54]
Srivastava, S.; Sammi, S.R.; Laxman, T.S.; Pant, A.; Nagar, A.; Trivedi, S. Silymarin promotes longevity and alleviates Parkinson’s associated pathologies in Caenorhabditis elegans. J. Funct. Foods,  2017, 31, 32-43.

[55]
Cho, J.K.; Park, J.W.; Song, S.C. Injectable and biodegradable poly(organophosphazene) gel containing silibinin: its physicochemical properties and anticancer activity. J. Pharm. Sci.,  2012, 101(7), 2382-2391.
 [http://dx.doi.org/10.1002/jps.23137] [PMID: 22487867]

[56]
Banerjee, S.; Samanta, R.; Pattnaik, A.K.; Pradhan, K.K.; Mehta, B.K.; Pattanayak, S.P. Wound healing activity of silibinin in mice. Pharmacognosy Res.,  2016, 8(4), 298-302.
 [http://dx.doi.org/10.4103/0974-8490.188880] [PMID: 27695272]

[57]
Varghese, L.; Agarwal, C.; Tyagi, A.; Singh, R.P.; Agarwal, R. Silibinin efficacy against human hepatocellular carcinoma. Clin. Cancer Res.,  2005, 11(23), 8441-8448.
 [http://dx.doi.org/10.1158/1078-0432.CCR-05-1646] [PMID: 16322307]

[58]
Mäser, P.; Vogel, D.; Schmid, C.; Räz, B.; Kaminsky, R. Identification and characterization of trypanocides by functional expression of an adenosine transporter from Trypanosoma brucei in yeast. J. Mol. Med. (Berl.),  2001, 79(2-3), 121-127.
 [http://dx.doi.org/10.1007/s001090000169] [PMID: 11357935]

[59]
Puisieux, A.; Galvin, K.; Troalen, F.; Bressac, B.; Marcais, C.; Galun, E.; Ponchel, F.; Yakicier, C.; Ji, J.; Ozturk, M. Retinoblastoma and p 53 tumor suppressor genes in human hepatoma cell lines. FASEB J.,  1993, 7(14), 1407-1413.
 [http://dx.doi.org/10.1096/fasebj.7.14.8224613] [PMID: 8224613]

[60]
Szabo, S.; Kusstatscher, S.; Sakoulas, G.; Sandor, Z.; Vincze, Á.; Jadus, M. Growth factors: new ‘endogenous drugs’ for ulcer healing. Scand. J. Gastroenterol.,  1995, 30(sup210), 15-18.
 [http://dx.doi.org/10.3109/00365529509090262] [PMID: 8578198]

[61]
DiPaola, R.S. To arrest or not to G(2)-M Cell-cycle arrest: commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin. cancer res., 8: 3512-3519, 2002. Clin. Cancer Res.,  2002, 8(11), 3311-3314.
 [PMID: 12429616]

[62]
Saller, R.; Brignoli, R.; Melzer, J.; Meier, R. An updated systematic review with 545 meta-analysis for the clinical evidence of silymarin. Forsch. Compl. Med.,  2008, 15(1), 9-20.
 [http://dx.doi.org/10.1159/000113648]

[63]
Wagoner, J.; Negash, A.; Kane, O.J.; Martinez, L.E.; Nahmias, Y.; Bourne, N.; Owen, D.M.; Grove, J.; Brimacombe, C.; McKeating, J.A.; Pécheur, E.I.; Graf, T.N.; Oberlies, N.H.; Lohmann, V.; Cao, F.; Tavis, J.E.; Polyak, S.J. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology,  2010, 51(6), 1912-1921.
 [http://dx.doi.org/10.1002/hep.23587] [PMID: 20512985]

[64]
Rawat, D.; Shrivastava, S.; Naik, R.A.; Chhonker, S.K.; Mehrotra, A.; Koiri, R.K. An overview of natural plant products in the treatment of hepatocellular carcinoma. Anticancer. Agents Med. Chem.,  2019, 18(13), 1838-1859.
 [http://dx.doi.org/10.2174/1871520618666180604085612] [PMID: 29866017]

[65]
Agarwal, R.; Agarwal, C.; Ichikawa, H.; Singh, R.P.; Aggarwal, B.B. Anticancer potential of silymarin: from bench to bed side. Anticancer Res.,  2006, 26(6B), 4457-4498.
 [PMID: 17201169]

[66]
Li, Y.J.; Li, Y.J.; Yang, L.D.; Zhang, K.; Zheng, K.Y.; Wei, X.M.; Yang, Q.; Niu, W.M.; Zhao, M.G.; Wu, Y.M. Silibinin exerts antidepressant effects by improving neurogenesis through BDNF/TrkB pathway. Behav. Brain Res.,  2018, 348, 184-191.
 [http://dx.doi.org/10.1016/j.bbr.2018.04.025] [PMID: 29680784]

[67]
Lim, R.; Morwood, C.J.; Barker, G.; Lappas, M. Effect of silibinin in reducing inflammatory pathways in in vitro and in vivo models of infection-induced preterm birth. PLoS One,  2014, 9(3)e92505
 [http://dx.doi.org/10.1371/journal.pone.0092505] [PMID: 24647589]

[68]
Zi, X.; Agarwal, R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention. Proc. Natl. Acad. Sci. USA,  1999, 96(13), 7490-7495.
 [http://dx.doi.org/10.1073/pnas.96.13.7490] [PMID: 10377442]

[69]
Chu, C.; Li, D.; Zhang, S.; Ikejima, T.; Jia, Y.; Wang, D.; Xu, F. Role of silibinin in the management of diabetes mellitus and its complications. Archives Pharmacal Res.,  2018, 41(8), 785-796.
 [http://dx.doi.org/10.1007/s12272-018-1047-x]

[70]
Singh, R.P.; Agarwal, R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur. J. Cancer,  2005, 41(13), 1969-1979.
 [http://dx.doi.org/10.1016/j.ejca.2005.03.033] [PMID: 16084079]

[71]
Astrup, A.; Finer, N. Redefining type 2 diabetes: ‘diabesity’ or ‘obesity dependent diabetes mellitus’? Obes. Rev.,  2000, 1(2), 57-59.
 [http://dx.doi.org/10.1046/j.1467-789x.2000.00013.x] [PMID: 12119987]

[72]
Radhika, M.I.; Ezhilarasan, D.; Gopinath, P. Antimicrobial efficacy of silymarin and silibinin against oral microorganisms. J. Microbiol. Infect. Dis.,  2017, 7(03), 139-143.
 [http://dx.doi.org/10.5799/jmid.367545]

[73]
Ullah, H.; Khan, H. Anti-Parkinson potential of silymarin: mechanistic insight and therapeutic standing. Front. Pharmacol.,  2018, 9, 422.
 [http://dx.doi.org/10.3389/fphar.2018.00422] [PMID: 29755356]

[74]
Zhang, Y.; Li, Q.; Ge, Y.; Chen, Y.; Chen, J.; Dong, Y.; Shi, W. Silibinin triggers apoptosis and cell-cycle arrest of SGC7901 cells. Phytother. Res.,  2013, 27(3), 397-403.
 [http://dx.doi.org/10.1002/ptr.4733] [PMID: 22619007]

[75]
Basiglio, C.L.; Sánchez Pozzi, E.J.; Mottino, A.D.; Roma, M.G. Differential effects of silymarin and its active component silibinin on plasma membrane stability and hepatocellular lysis. Chem. Biol. Interact.,  2009, 179(2-3), 297-303.
 [http://dx.doi.org/10.1016/j.cbi.2008.12.008] [PMID: 19135039]

[76]
Araujo, F.B.; Barbosa, D.S.; Hsin, C.Y.; Maranhão, R.C.; Abdalla, D.S.P. Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis,  1995, 117(1), 61-71.
 [http://dx.doi.org/10.1016/0021-9150(94)05558-Z] [PMID: 8546756]

[77]
Chen, K.; Xu, J.; He, H.; Zhao, L.; Xiong, J.; Mo, Z. Protective effect of silibinin on islet β cells in C57BL/6J mice fed a high fat diet. Zhong Nan Da Xue Xue Bao Yi Xue Ban,  2015, 40(2), 165-170.
 [http://dx.doi.org/10.11817/j.issn.1672-7347.2015.02.008] [PMID: 25769325]

[78]
Amin, M.M.; Arbid, M.S. Estimation of the novel antipyretic, anti-inflammatory, antinociceptive and antihyperlipidemic effects of silymarin in Albino rats and mice. Asian Pac. J. Trop. Biomed.,  2015, 5(8), 619-623.
 [http://dx.doi.org/10.1016/j.apjtb.2015.05.009]

[79]
Gosert, R.; Egger, D.; Lohmann, V.; Bartenschlager, R.; Blum, H.E.; Bienz, K.; Moradpour, D. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J. Virol.,  2003, 77(9), 5487-5492.
 [http://dx.doi.org/10.1128/JVI.77.9.5487-5492.2003] [PMID: 12692249]

[80]
Bouderba, S.; Sanchez-Martin, C.; Villanueva, G.R.; Detaille, D.; Koceïr, E.A. Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes. J. Diabetes,  2014, 6(2), 184-192.
 [http://dx.doi.org/10.1111/1753-0407.12083] [PMID: 23953934]

[81]
Ahmed Aziz, T.; Hasan Marouf, B.; Aorahman Ahmed, Z.; Abdulrahman Hussain, S. Anti-inflammatory activity of silibinin in animal models of chronic inflammation. Am. J. Pharmacol. Sci.,  2014, 2(1), 7-11.
 [http://dx.doi.org/10.12691/ajps-2-1-2]

[82]
Park; Kim, K.A.; Kwon, K.B.; Park, J.W.; Park, B.H. Silibinin attenuates adipogenesis in 3T3-L1 preadipocytes through a potential upregulation of the insig pathway. Int. J. Mol. Med.,  2009, 23(5), 633-637.
 [http://dx.doi.org/10.3892/ijmm_00000174] [PMID: 19360322]

[83]
Jin, G.; Bai, D.; Yin, S.; Yang, Z.; Zou, D.; Zhang, Z.; Li, X.; Sun, Y.; Zhu, Q. Silibinin rescues learning and memory deficits by attenuating microglia activation and preventing neuroinflammatory reactions in SAMP8 mice. Neurosci. Lett.,  2016, 629, 256-261.
 [http://dx.doi.org/10.1016/j.neulet.2016.06.008] [PMID: 27276653]

[84]
Song, X.; Zhou, B.; Cui, L.; Lei, D.; Zhang, P.; Yao, G.; Xia, M.; Hayashi, T.; Hattori, S.; Ushiki-Kaku, Y.; Tashiro, S.; Onodera, S.; Ikejima, T. Silibinin ameliorates Aβ25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress. Neurochem. Res.,  2017, 42(4), 1073-1083.
 [http://dx.doi.org/10.1007/s11064-016-2141-4] [PMID: 28004303]

[85]
Yin, F.; Liu, J.; Ji, X.; Wang, Y.; Zidichouski, J.; Zhang, J. Silibinin: A novel inhibitor of Aβ aggregation. Neurochem. Int.,  2011, 58(3), 399-403.
 [http://dx.doi.org/10.1016/j.neuint.2010.12.017] [PMID: 21185897]

[86]
Jayaraj, R.L.; Beiram, R.; Azimullah, S.; Meeran, M.F.N.; Ojha, S.K.; Adem, A.; Jalal, F.Y. Lycopodium attenuates loss of dopaminergic neurons by suppressing oxidative stress and neuroinflammation in a rat model of Parkinson’s disease. Molecules,  2019, 24(11), 2182.
 [http://dx.doi.org/10.3390/molecules24112182] [PMID: 31185705]

[87]
Juma’a, K.M.; Ahmed, Z.A.; Numan, I.T.; Hussain, S.A. Dose-dependent anti-inflammatory effect of silymarin in experimental animal model of chronic inflammation. Afr. J. Pharm. Pharmacol.,  2009, 3(5), 242-247.

[88]
Liu, X.; Liu, W.; Wang, C.; Chen, Y.; Liu, P.; Hayashi, T.; Mizuno, K.; Hattori, S.; Fujisaki, H.; Ikejima, T. Silibinin attenuates motor dysfunction in a mouse model of Parkinson’s disease by suppression of oxidative stress and neuroinflammation along with promotion of mitophagy. Physiol. Behav.,  2021, 239113510
 [http://dx.doi.org/10.1016/j.physbeh.2021.113510] [PMID: 34181930]

[89]
Sian, J.; Dexter, D.T.; Lees, A.J.; Daniel, S.; Agid, Y.; Javoy-Agid, F.; Jenner, P.; Marsden, C.D. Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol.,  1994, 36(3), 348-355.
 [http://dx.doi.org/10.1002/ana.410360305] [PMID: 8080242]

[90]
Křen, V.; Walterová, D. Silybin and silymarin - new effects and applications. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.,  2005, 149(1), 29-41.
 [http://dx.doi.org/10.5507/bp.2005.002] [PMID: 16170386]

[91]
Bannwart, C.F.; Peraçoli, J.C.; Nakaira-Takahagi, E.; Peraçoli, M.T.S. Inhibitory effect of silibinin on tumour necrosis factor-alpha and hydrogen peroxide production by human monocytes. Nat. Prod. Res.,  2010, 24(18), 1747-1757.
 [http://dx.doi.org/10.1080/14786410903314492] [PMID: 20981616]

[92]
Gazák, R.; Walterová, D.; Kren, V. Silybin and silymarin--new and emerging applications in medicine. Curr. Med. Chem.,  2007, 14(3), 315-338.
 [http://dx.doi.org/10.2174/092986707779941159] [PMID: 17305535]

[93]
Gobalakrishnan, S.; Asirvatham, S.S.; Janarthanam, V. Effect of silybin on lipid profile in hypercholesterolaemic rats. J. Clin. Diagn. Res.,  2016, 10(4), FF01-FF05.
 [http://dx.doi.org/10.7860/JCDR/2016/16393.7566] [PMID: 27190826]

[94]
Liu, C.H.; Lin, C.C.; Hsu, W.C.; Chung, C.Y.; Lin, C.C.; Jassey, A.; Chang, S.P.; Tai, C.J.; Tai, C.J.; Shields, J.; Richardson, C.D.; Yen, M.H.; Tyrrell, D.L.J.; Lin, L.T. Highly bioavailable silibinin nanoparticles inhibit HCV infection. Gut,  2017, 66(10), 1853-1861.
 [http://dx.doi.org/10.1136/gutjnl-2016-312019] [PMID: 27436270]

[95]
Ahmed-Belkacem, A.; Ahnou, N.; Barbotte, L.; Wychowski, C.; Pallier, C.; Brillet, R.; Pohl, R.T.; Pawlotsky, J.M. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology,  2010, 138(3), 1112-1122.
 [http://dx.doi.org/10.1053/j.gastro.2009.11.053] [PMID: 19962982]

[96]
Mateen, S.; Raina, K.; Agarwal, R. Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer. Nutr. Cancer,  2013, 65(sup1 Suppl. 1), 3-11.
 [http://dx.doi.org/10.1080/01635581.2013.785004] [PMID: 23682778]

[97]
Singh, R.P.; Mallikarjuna, G.U.; Sharma, G.; Dhanalakshmi, S.; Tyagi, A.K.; Chan, D.C.F.; Agarwal, C.; Agarwal, R. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin. Cancer Res.,  2004, 10(24), 8641-8647.
 [http://dx.doi.org/10.1158/1078-0432.CCR-04-1435] [PMID: 15623648]

[98]
Manna, S.K.; Mukhopadhyay, A.; Van, N.T.; Aggarwal, B.B. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J. Immunol.,  1999, 163(12), 6800-6809.
 [PMID: 10586080]

[99]
Umetsu, T.; Inoue, J.; Kogure, T.; Kakazu, E.; Ninomiya, M.; Iwata, T.; Takai, S.; Nakamura, T.; Sano, A.; Shimosegawa, T. Inhibitory effect of silibinin on hepatitis B virus entry. Biochem. Biophys. Rep.,  2018, 14, 20-25.
 [http://dx.doi.org/10.1016/j.bbrep.2018.03.003] [PMID: 29872730]

[100]
Liu, W.; Li, Y.; Zheng, X.; Zhang, K.; Du, Z. Potent inhibitory effect of silibinin from milk thistle on skin inflammation stimuli by 12-O-tetradecanoylphorbol-13-acetate. Food Funct.,  2015, 6(12), 3712-3719.
 [http://dx.doi.org/10.1039/C5FO00899A] [PMID: 26345246]

[101]
Tota, S.; Kamat, P.K.; Shukla, R.; Nath, C. Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behav. Brain Res.,  2011, 221(1), 207-215.
 [http://dx.doi.org/10.1016/j.bbr.2011.02.041] [PMID: 21382422]

[102]
Singh, R.P.; Dhanalakshmi, S.; Tyagi, A.K.; Chan, D.C.; Agarwal, C.; Agarwal, R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res.,  2002, 62(11), 3063-3069.
 [PMID: 12036915]

[103]
Tabandeh, M.R.; Oryan, A.; Mohhammad-Alipour, A.; Tabatabaei-Naieni, A. Silibinin regulates matrix metalloproteinase 3 (stromelysine1) gene expression, hexoseamines and collagen production during rat skin wound healing. Phytother. Res.,  2013, 27(8), 1149-1153.
 [http://dx.doi.org/10.1002/ptr.4839] [PMID: 22976003]

[104]
Oduola, T.; Bello, I.; Adeosun, G.; Ademosun, A.W.; Raheem, G.; Avwioro, G. Hepatotoxicity and nephrotoxicity evaluation in Wistar albino rats exposed to Morinda lucida leaf extract. N. Am. J. Med. Sci.,  2010, 2(5), 230-233.
 [http://dx.doi.org/10.4297/najms.2010.2230] [PMID: 22574294]

[105]
Das, S.K.; Mukherejee, S.; Vasudevan, D.M. Medical properties of milk thistle with special reference to silymarin an overview. Nat. Prod. Rad,  2008, 7, 182-192.

[106]
Rolo, A.P.; Oliveira, P.J.; Moreno, A.J.; Palmeira, C.M. Protection against post-ischemic mitochondrial injury in rat liver by silymarin or TUDC. Hepatol. Res.,  2003, 26-, 217, 224.
 [http://dx.doi.org/10.1016/S1386-6346(03)00108-6]

[107]
Guigas, B.; Naboulsi, R.; Villanueva, G.R.; Taleux, N.; Lopez-Novoa, J.M.; Leverve, X.M.; El-Mir, M.Y. The flavonoid silibinin decreases glucose-6-phosphate hydrolysis in perfused rat hepatocytes by an inhibitory effect on glucose-6-phosphatase. Cell. Physiol. Biochem.,  2007, 20(6), 925-934.
 [http://dx.doi.org/10.1159/000110453] [PMID: 17982275]

[108]
McClure, J.; Margineantu, D.H.; Sweet, I.R.; Polyak, S.J. Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism. Virology,  2014, 449, 96-103.
 [http://dx.doi.org/10.1016/j.virol.2013.11.003] [PMID: 24418542]

[109]
Comoglio, A.; Leonarduzzi, G.; Carini, R.; Busolin, D.; Basaga, H.; Albano, E.; Tomasi, A.; Poli, G.; Morazzoni, P.; Magistretti, M.J. Studies on the antioxidant and free radical scavenging properties of IdB 1016 a new flavanolignan complex. Free Radic. Res. Commun.,  1990, 11(1-3), 109-115.
 [http://dx.doi.org/10.3109/10715769009109673] [PMID: 2074043]

[110]
Valenzuela, A.; Guerra, R.; Videla, L. Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Med.,  1986, 52(6), 438-440.
 [http://dx.doi.org/10.1055/s-2007-969247] [PMID: 3562659]

[111]
Nambiar, D.; Prajapati, V.; Agarwal, R.; Singh, R.P. In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells. Cancer Lett., 2012.
 [http://dx.doi.org/10.1016/j.canlet.2012.09.004] [PMID: 23022268]

[112]
Müzes, G.; Deák, G.; Láng, I.; Nékám, K.; Gergely, P.; Fehér, J. Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme. Acta Physiol. Hung.,  1991, 78(1), 3-9.
 [PMID: 1763650]

[113]
Freundenberg, K.; Neish, A. Constitution and Biosynthesis of Lignins; Molecular Biology. In: Biochemistry and Biophysics. Springer,: 1968, 2, 132.

[114]
Vue, B.; Zhang, S.; Zhang, X.; Parisis, K.; Zhang, Q.; Zheng, S.; Wang, G.; Chen, Q.H. Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations. Eur. J. Med. Chem.,  2016, 109, 36-46.
 [http://dx.doi.org/10.1016/j.ejmech.2015.12.041] [PMID: 26748997]

[115]
Carini, R.; Comoglio, A.; Albano, E.; Poli, G. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Biochem. Pharmacol.,  1992, 43(10), 2111-2115.
 [http://dx.doi.org/10.1016/0006-2952(92)90168-I] [PMID: 1599497]

[116]
Antonietta, P.M.; Cianciulli, A. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson’s disease. Curr. Pharm. Des.,  2012, 18(2), 200-208.
 [http://dx.doi.org/10.2174/138161212799040574]

[117]
Kang, S.N.; Lee, M.H.; Kim, K.M.; Cho, D.; Kim, T.S. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C 1 1Abbreviations: 1,25-(OH)2D3, 1α,25-dihydroxyvitamin D3; ERK, extracellular signal-regulated kinase; mAb, monoclonal antibody; MAPK, mitogen-activated protein kinase; NBT, nitroblue tetrazolium; and PKC, protein kinase C. Biochem. Pharmacol.,  2001, 61(12), 1487-1495.
 [http://dx.doi.org/10.1016/S0006-2952(01)00626-8] [PMID: 11377378]

[118]
Kroll, D.J.; Shaw, H.S.; Oberlies, N.H. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr. Cancer Ther.,  2007, 6(2), 110-119.
 [http://dx.doi.org/10.1177/1534735407301825] [PMID: 17548790]

[119]
Šimánek, V. Křen, V.; Ulrichová, J.; Vicar, J.; Cvak, L. Silymarin: What is in the name? An appeal for a change of editorial policy. Hepatology,  2000, 32(2), 442-444.
 [http://dx.doi.org/10.1053/jhep.2000.9770] [PMID: 10960282]

[120]
Tentillier, N.; Etzerodt, A.; Olesen, M.N.; Rizalar, F.S.; Jacobsen, J.; Bender, D.; Moestrup, S.K.; Romero-Ramos, M. Anti-inflammatory modulation of microglia via CD163-targeted glucocorticoids protects dopaminergic neurons in the 6-OHDA parkinson’s disease model. J. Neurosci.,  2016, 36(36), 9375-9390.
 [http://dx.doi.org/10.1523/JNEUROSCI.1636-16.2016] [PMID: 27605613]

[121]
Lee, B; Choi, GM; Sur, B Silibinin prevents depression-like behaviors in a single prolonged stress rat model: the possible role of serotonin. BMC complement. med. ther.,  2020, 20(1), 1-2.
 [http://dx.doi.org/10.1186/s12906-020-2868-y]

[122]
Liu, C.H.; Jassey, A.; Hsu, H.Y.; Lin, L.T. Antiviral activities of silymarin and derivatives. Molecules,  2019, 24(8), 1552.
 [http://dx.doi.org/10.3390/molecules24081552] [PMID: 31010179]

[123]
Bosch-Barrera, J.; Martin-Castillo, B.; Buxó, M.; Brunet, J.; Encinar, J.A.; Menendez, J.A. Silibinin and SARS-CoV-2: dual targeting of host cytokine storm and virus replication machinery for clinical management of COVID-19 patients. J. Clin. Med.,  2020, 9(6), 1770.
 [http://dx.doi.org/10.3390/jcm9061770] [PMID: 32517353]

[124]
Blaising, J.; Lévy, P.L.; Gondeau, C.; Phelip, C.; Varbanov, M.; Teissier, E.; Ruggiero, F.; Polyak, S.J.; Oberlies, N.H.; Ivanovic, T.; Boulant, S.; Pécheur, E.I. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell. Microbiol.,  2013, 15(11), n/a.
 [http://dx.doi.org/10.1111/cmi.12155] [PMID: 23701235]

[125]
Esser-Nobis, K.; Romero-Brey, I.; Ganten, T.M.; Gouttenoire, J.; Harak, C.; Klein, R.; Schemmer, P.; Binder, M.; Schnitzler, P.; Moradpour, D.; Bartenschlager, R.; Polyak, S.J.; Stremmel, W.; Penin, F.; Eisenbach, C.; Lohmann, V. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology,  2013, 57(3), 953-963.
 [http://dx.doi.org/10.1002/hep.26260] [PMID: 23322644]

[126]
Fall, C.P.; Bennett, J.P. Jr Characterization and time course of MPP+-induced apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci. Res.,  1999, 55(5), 620-628.
 [http://dx.doi.org/10.1002/(SICI)1097-4547(19990301)55:5<620:AID-JNR9>3.0.CO;2-S] [PMID: 10082084]

[127]
Gowtham, R.; Yousuf, M.A.F.; Ezhilarasan, D.; Sambantham, S.; Anandan, B. In vitro antifungal effects of hesperetin and silibinin. Pharmacogn. J.,  2018, 10(4), 789-792.
 [http://dx.doi.org/10.5530/pj.2018.4.133]

[128]
Geed, M.; Garabadu, D.; Ahmad, A.; Krishnamurthy, S. Silibinin pretreatment attenuates biochemical and behavioral changes induced by intrastriatal MPP+ injection in rats. Pharmacol. Biochem. Behav.,  2014, 117, 92-103.
 [http://dx.doi.org/10.1016/j.pbb.2013.12.008] [PMID: 24345573]

[129]
Li, H.B.; Yang, Y.R.Y.; Mo, Z.J.; Ding, Y.; Jiang, W.J. Silibinin improves palmitate-induced insulin resistance in C2C12 myotubes by attenuating IRS-1/PI3K/Akt pathway inhibition. Braz. J. Med. Biol. Res.,  2015, 48(5), 440-446.
 [http://dx.doi.org/10.1590/1414-431x20144238] [PMID: 25760026]

[130]
Camini, F.C.; da Silva, T.F.; da Silva Caetano, C.C.; Almeida, L.T.; Ferraz, A.C.; Alves Vitoreti, V.M.; de Mello Silva, B.; de Queiroz Silva, S.; de Magalhães, J.C.; de Brito Magalhães, C.L. Antiviral activity of silymarin against Mayaro virus and protective effect in virus-induced oxidative stress. Antiviral Res.,  2018, 158, 8-12.
 [http://dx.doi.org/10.1016/j.antiviral.2018.07.023] [PMID: 30076863]

[131]
Wang, Q.; Liu, M.; Liu, W.W.; Hao, W.B.; Tashiro, S.; Onodera, S.; Ikejima, T. In vivo recovery effect of silibinin treatment on streptozotocin-induced diabetic mice is associated with the modulations of sirt-1 expression and autophagy in pancreatic β-cell. J. Asian Nat. Prod. Res.,  2012, 14(5), 413-423.
 [http://dx.doi.org/10.1080/10286020.2012.657180] [PMID: 22423887]

[132]
Colturato, C.P.; Constantin, R.P.; Maeda, A.S., Jr; Constantin, R.P.; Yamamoto, N.S.; Bracht, A.; Ishii-Iwamoto, E.L.; Constantin, J. Metabolic effects of silibinin in the rat liver. Chem. Biol. Interact.,  2012, 195(2), 119-132.
 [http://dx.doi.org/10.1016/j.cbi.2011.11.006] [PMID: 22137898]

[133]
Lu, P.; Mamiya, T.; Lu, L.L.; Mouri, A.; Niwa, M.; Hiramatsu, M.; Zou, L.B.; Nagai, T.; Ikejima, T.; Nabeshima, T. Silibinin attenuates amyloid beta(25-35) peptide-induced memory impairments: implication of inducible nitric-oxide synthase and tumor necrosis factor-alpha in mice. J. Pharmacol. Exp. Ther.,  2009, 331(1), 319-326.
 [http://dx.doi.org/10.1124/jpet.109.155069] [PMID: 19638571]

[134]
Duan, S.; Guan, X.; Lin, R.; Liu, X.; Yan, Y.; Lin, R.; Zhang, T.; Chen, X.; Huang, J.; Sun, X.; Li, Q.; Fang, S.; Xu, J.; Yao, Z.; Gu, H. Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: a dual-target drug for the treatment of Alzheimer’s disease. Neurobiol. Aging,  2015, 36(5), 1792-1807.
 [http://dx.doi.org/10.1016/j.neurobiolaging.2015.02.002] [PMID: 25771396]

[135]
Rasool, N.; Qaddir, I.; Hussain, W.; Mahmood, S. Computer-aided analysis of phytochemicals as potential dengue virus inhibitors based on molecular docking, ADMET and DFT studies. J. Vector Borne Dis.,  2017, 54(3), 255-262.
 [http://dx.doi.org/10.4103/0972-9062.217617] [PMID: 29097641]

[136]
Song, J.H.; Choi, H.J. Silymarin efficacy against influenza A virus replication. Phytomedicine,  2011, 18(10), 832-835.
 [http://dx.doi.org/10.1016/j.phymed.2011.01.026] [PMID: 21377857]

[137]
Molavi, O.; Narimani, F.; Asiaee, F.; Sharifi, S.; Tarhriz, V.; Shayanfar, A.; Hejazi, M.; Lai, R. Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy. Pharm. Biol.,  2017, 55(1), 729-739.
 [http://dx.doi.org/10.1080/13880209.2016.1270972] [PMID: 28027688]

[138]
Yu, H.C.; Chen, L.J.; Cheng, K.C.; Li, Y.X.; Yeh, C.H.; Cheng, J.T. Silymarin inhibits cervical cancer cell through an increase of phosphatase and tensin homolog. Phytother. Res.,  2012, 26(5), 709-715.
 [http://dx.doi.org/10.1002/ptr.3618] [PMID: 22016029]

[139]
Pashaei-Asl, F.; Pashaei-Asl, R.; Khodadadi, K.; Akbarzadeh, A.; Ebrahimie, E.; Pashaiasl, M. Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer. Artif. Cells Nanomed. Biotechnol.,  2018, 46(7), 1483-1487.
 [http://dx.doi.org/10.1080/21691401.2017.1374281] [PMID: 28884602]

[140]
Patel, S.; Waghela, B.; Shah, K.; Vaidya, F.; Mirza, S.; Patel, S.; Pathak, C.; Rawal, R. Silibinin, A natural blend in polytherapy formulation for targeting Cd44v6 expressing colon cancer stem cells. Sci. Rep.,  2018, 8(1), 16985.
 [http://dx.doi.org/10.1038/s41598-018-35069-0] [PMID: 29311619]

[141]
Tyagi, A.; Agarwal, C.; Harrison, G.; Glode, L.M.; Agarwal, R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis,  2004, 25(9), 1711-1720.
 [http://dx.doi.org/10.1093/carcin/bgh180] [PMID: 15117815]

[142]
Cai, J.Y.; Li, J.; Hou, Y.N.; Ma, K.; Yao, G.D.; Liu, W.W.; Hayashi, T.; Itoh, K.; Tashiro, S.I.; Onodera, S.; Ikejima, T. Concentration-dependent dual effects of silibinin on kanamycin-induced cells death in Staphylococcus aureus. Biomed. Pharmacother.,  2018, 102, 782-791.
 [http://dx.doi.org/10.1016/j.biopha.2018.03.133]

[143]
Yun, D.G.; Lee, D.G. Assessment of silibinin as a potential antifungal agent and investigation of its mechanism of action. IUBMB Life,  2017, 69(8), 631-637.
 [http://dx.doi.org/10.1002/iub.1647] [PMID: 28636236]

[144]
Donald, L. Topical liposome compositions containing phenolic anti-inflammatory agents and their methods. US2015/03422843A1, 2015.

[145]
Lian, Y.; Hong, T.; Cheng, X.; Duan, Z. Method for producing silymarin. WO 2015/100524 A1, 2015.

[146]
Cornblatt, B.; Cornblatt, G.; Bzhelyansky, A.; Henderson, R. Composition comprising sulforaphane or a sulforaphane precursors & a milk thistle extract or powder. US2015/ 0118306 A1, 2015.

[147]
Xu, X.; Yu, J.; Cao, X.; Zhu, Y. Formulation of silibinin with high efficccy & prolonged action & preparation method. US 9,023, 388 B2, 2015.

[148]
Perry, A.W. Stabilized L-Ascorbic acid skin serum. US 9, 468,597 B1, 2016.

[149]
Chun, C.L.; Lin, L.T.; Richardson, C.D. HSU, Wen-Chen Silibinin nanoparticle & a method of treating hepatitis C. US 2016/0324795A1, 2016.

[150]
Chen, J.; Gao, B.; Zhou, Q.; Zhou, S.; Nan, C.; Zhang, Y.; Chan, W.; Chen, L.; Liu, W. Silybin injection & preparation method. WO2016/110193A1, 2016.

[151]
Lin, J.W. Method of preventing or treating spinocerebellar ataxia by administrating silibinin. US 2017/0246144 A1, 2017.

[152]
De, I.G.; Monica, F.; Di, M.; Carlo, M. An oral drug formulation comprising silybin. WO2017/ 081140 A1, 2017.

[153]
Viktororich, M.V. Oral pharmaceutical composition for the treatment of inflammatory gastrointestinal diseases. EP 2 767 286 B1, 2018.

[154]
Amoabediny, G.; Ochi, M.M.; Ochi, S.M.; Rezayat, S.M.; Akbarzadeh, A.; Ebrahimi, B. Targeted nano-liposome co-entraping anticancer drugs. US 9, 855, 216 B2, 2018.

[155]
Humphreys, J.; Sabour, M. Compositions for improving the health of hair, skin & nails. US Patent US2018/0028424 A1, 2018.

[156]
Clark, J. Compositions & methods for reducing local and systemic risks of envenomation. WO2018/195082 A1, 2018.

[157]
Peter, F.; Ulrich, M.; Pohl, R.T.T.; Claudio, R.L. Silibinin component for the treatment of hepatitis. EP 2 392 326 B1, 2018.

[158]
Pacheco, T.; Anchordoquy, T.; Aggarwal, R.; Singh, N.T. Topical silibinin formulations & uses. US 2018/0280343 A1, 2018.

[159]
Prous, S.R.; Daltell, A.M.; Gonzalez, A.V. Enhanced solubility of milk thistle extract. US 2019/0091273 A1, 2019.

[160]
Carmelina, L.; Alessandro, F.; Paola, S. Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis. EP 2 976 075 B1, 2019.

[161]
Yoshiki, N.; Takeshi, O.; Hirofumi, N.; Chika, S. Method for preventing incorporation of undifferentiated IPS cells possibly having tumorigenic potential using differentiation controlling compound. WO 2019/187918 A1, 2019.

[162]
Yan, X.; Wu, N.; Sun, H. Pharmaceutical composition containing silibinin & pueraria root extract. US10, 376491 B2, 2019.

[163]
Rita, B.A.; Luisa, B.M.; Gennara, C.; Grazia, C.; Letizia, M.; Fabiola, C.E.; Gaetano, G.; Mariano, L.; Giovanna, P.; Santa, V. Nanostructured formulations for the delivery of silibinin & other active ingredients for treating ocular diseases. EP 3 203 989 B1, 2019.

[164]
Shi, D.; Fu, C.; Cheng, X.; Gong, W.; Gu, J.; Li, P.; Zhang, M. Compound for the treatment or prevention of liver diseases. WO 2019/233440 A1, 2019.

[165]
Ju, X.; Liang, C.; Tian, B.; Liu, Y.; Tian, L.; Mao, G.; Wang, L.; He, Y.; Wang, Y.; Xu, J.; Yang, D.; Qi, L.; Yao, W.; Zhao, Q.; Li, H. Silibinin 3,3’’-thiodipropionic acid ester with hepatoprotective activity. US 10,766,885 B1, 2020.

[166]
Clark, A.J. Composition and method for reducing local & systemic risks of envenomation. US 2020/0360405 A1, 2020.

[167]
Cornblatt, B.; Cornblatt, G.; Bzhelyansky, A.; Henderson, R. Composition comprising sulforaphane or a sulforaphane precursors & a milk thistle extract or powder. US 10,688,158 B2, 2020.

[168]
James, D.P.; Rajewski, R.A.; Mainous, B. Compositions containing silymarin & sulfoalky ether cyclodextrin & method of using. US 10, 702, 568 B2, 2020.

[169]
Wu, N.; Xijun, Y.; He, S.; Kaujing, Y.; Yonghong, Z.; Shunnan, Z.; Xiaolin, B.; Yi, H. Pharmaceutical formulation comprising silybin & puer tea essence. EP 3 275 457 B1, 2021.

[170]
Joost, V.; Sharon, R. Treatment of Sebaceous gland doisorders.WO 2021/018934 A1, 2021.

[171]
Joost, V. Treatment of inflammatory skin conditions. WO 2021/018936 A1, 2021.

[172]
Yun, X.; Wu, N.; He, S.; Yan, K.; Zhu, Y.; Ma, X.; Zhang, S.; Li, C.; Bai, X.; Ting, L.; Lei, L. Pharmaceutical composition containing silibinin & pueraria root extract. EP 3275456 B1, 2021.

[173]
Ju, X.; Liang, C.; Liu, Y.; Tian, B.; Tian, L.; Mao, G.; Wang, L. Silibinin lipoic acid ester acid hepatoprotective activity & amethod of preparing. US2021/0347767A1, 2021.

[174]
He, S.; Wu, N. Pharmaceutical composition containing silybin & L-carnitine. EP3 275 455 B1, 2021.
Cite As
Current Bioactive Compounds

Possible Mechanism and Pharmacological Activities of a Flavolignan Silibinin

Abstract

Graphical Abstract
